Intellia Therapeutics (NTLA) Receivables (2015 - 2026)
Intellia Therapeutics (NTLA) reported Receivables of $9.1 million for Q1 2026, down 1.09% year-over-year from $9.2 million in Q1 2025, and down 3.89% on a QoQ basis from $9.5 million in Q4 2025.
Intellia Therapeutics (NTLA) has 12 years of Receivables data on file, last reported at $9.1 million in Q1 2026.
- Quarterly Receivables fell 1.09% year-over-year to $9.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.1 million (down 1.09% YoY) and the FY2025 annual result came in at $9.5 million, up 31.5% from the prior year.
- Receivables declined to $9.1 million in Q1 2026 per NTLA's latest filing, from $9.5 million in the prior quarter.
- Across five years, Receivables topped out at $37.5 million in Q4 2023 and bottomed at $300000.0 in Q3 2024.
- The 5-year median for Receivables is $8.5 million (2024), against an average of $10.2 million.
- The widest annual swing landed in 2024, when Receivables sank 77.26%; it then jumped 3583.33% in 2025.
- Tracing NTLA's Receivables over 5 years: stood at $5.4 million in 2022, then surged by 597.76% to $37.5 million in 2023, then slumped by 77.26% to $8.5 million in 2024, then gained by 11.17% to $9.5 million in 2025, then decreased by 3.89% to $9.1 million in 2026.
- Per Business Quant, the three latest NTLA Receivables figures stand at $9.1 million (Q1 2026), $9.5 million (Q4 2025), and $11.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - | 9.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.10 Mn |
| Dec 31, 2025 | 9.47 Mn |
| Sep 30, 2025 | 11.05 Mn |
| Jun 30, 2025 | 10.20 Mn |
| Mar 31, 2025 | 9.20 Mn |
| Dec 31, 2024 | 8.52 Mn |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 11.50 Mn |
| Mar 31, 2024 | 36.43 Mn |
| Dec 31, 2023 | 37.46 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 6.46 Mn |
| Mar 31, 2023 | 5.21 Mn |
| Dec 31, 2022 | 5.37 Mn |
| Sep 30, 2022 | 5.02 Mn |
| Jun 30, 2022 | 2.85 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 2.13 Mn |
| Sep 30, 2021 | 4.59 Mn |
| Jun 30, 2021 | 1.99 Mn |
| Mar 31, 2021 | 1.00 Mn |
| Dec 31, 2020 | 2.13 Mn |
| Sep 30, 2020 | 2.42 Mn |
| Jun 30, 2020 | 7.76 Mn |
| Mar 31, 2020 | 21.77 Mn |
| Dec 31, 2019 | 8.22 Mn |
| Sep 30, 2019 | 4.60 Mn |
| Jun 30, 2019 | 4.20 Mn |
| Mar 31, 2019 | 3.60 Mn |
| Dec 31, 2018 | 13.55 Mn |
| Sep 30, 2018 | 3.81 Mn |
| Jun 30, 2018 | 8.60 Mn |
| Mar 31, 2018 | 8.47 Mn |
| Dec 31, 2017 | 16.47 Mn |
| Sep 30, 2017 | 5.49 Mn |
| Jun 30, 2017 | 3.76 Mn |
| Mar 31, 2017 | 3.44 Mn |
| Dec 31, 2016 | 6.95 Mn |
| Sep 30, 2016 | 2.11 Mn |
| Jun 30, 2016 | 2.00 Mn |
| Mar 31, 2016 | 2.00 Mn |
| Dec 31, 2015 | 7.00 Mn |